Table 3.
Condition | Targeting domain |
Reference |
---|---|---|
HCC | CD70/B7H3 | [189, 414, 432–434] |
GPC3/CD147 | ||
c-MET/PD-L1 | ||
GPC3/ASGR1 gp100/HER2 |
||
Glioma | CD70/B7H3 | [189, 374–376, 435, 436] |
HER2/IL13Rα2 | ||
EGFRvIII/IL13Rα2 OR EphA2; MOG/IL13Rα2 OR EphA2 | ||
EGFRvIII/IL13Rα2 OR CD133 | ||
HER2/IL13Rα2/EphA2 | ||
IL13Rα2/ EphA2 | ||
GC | Trop2/PD-L1 | [277] |
PC | MSLN/CEA | [437, 438] |
MSLN/PSMA | ||
EC | CD70/B7H3 | [189] |
CRC |
CD30/CEA; CD30/TAG70 |
[439] |
BC | CD70/B7H3 | [189, 414, 440–442] |
Her2/IGF1R | ||
MUC1/HER2 | ||
ROR1/B7H3 gp100/HER2 |
||
PCa | MSLN/PSMA | [437] |
LCa | CD70/B7H3 | [189, 204, 442] |
ROR1/B7H3 PSCA/MUC1 |
||
OC | FLOR1/MSLN | [330, 333, 334] |
ALPPL2/MCAM ALPPL2/MSLN ALPPL2/HER2 PD-L1/MUC16 |
||
MEL |
CD70/B7H3 gp100/CSPG4 gp100/VEGFR-2 |
[189, 314, 443] |